(Q40131713)

English

The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients

scientific article published on January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients (English)

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

author name string

Lisa M Demeter

1

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

A Lisa Mukherjee

2

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Robin DiFrancesco

3

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Hongyu Jiang

4

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Robert DiCenzo

5

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Barbara Bastow

6

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Alex R Rinehart

7

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Gene D Morse

8

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Mary Albrecht

9

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

1

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

61-72

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Blockade of HERG channels by HIV protease inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

22 September 2017

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Predictors of virological response to atazanavir in protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2821072

20 August 2018

A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0901-61

21 January 2018

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team

1 reference

https://pubmed.ncbi.nlm.nih.gov/18215983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array

1 reference

https://pubmed.ncbi.nlm.nih.gov/18215983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/18215983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1310/HCT0901-61

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40131713&oldid=1886439432"